PRME
Prime Medicine Inc

2,105
Loading...
Loading...
News
all
press releases
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -13.89% and -59.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·29d ago
News Placeholder
More News
News Placeholder
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks·1mo ago
News Placeholder
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech
Zacks·1mo ago
News Placeholder
Prime Medicine stock soars amid gene editing sector momentum
Investing.com -- Prime Medicine (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for Verve Therapeutics (NASDAQ:VERV) last month. 
investing.com·2mo ago
News Placeholder
Citi Downgrade Sparks Retail Chatter On Prime Medicine Amid Cash Runway Uncertainty
The biotech firm announced a restructuring to focus on its liver disease programs while cutting costs and workforce amid ongoing development challenges.
Stocktwits·3mo ago
News Placeholder
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
Zacks·4mo ago
News Placeholder
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish
The company said Keith Gottesdiener will step down as the chief executive, while CFO Allan Reine will succeed him.
Stocktwits·4mo ago
News Placeholder
Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 30, 2025 NEW YORK...
PR Newswire·7mo ago
News Placeholder
Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead
Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.
barchart.com·8mo ago
News Placeholder
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
read more...
Benzinga·11mo ago

Latest PRME News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.